MSD (@msdinvents) 's Twitter Profile
MSD

@msdinvents

We aspire to be the premier research-intensive biopharmaceutical company.

ID: 784066171008147456

linkhttps://www.msdprivacy.com/ calendar_today06-10-2016 16:21:57

2,2K Tweet

23,23K Followers

216 Following

MSD (@msdinvents) 's Twitter Profile Photo

Today, we announced that we’ve expanded our global development and commercialization agreement with Daiichi Sankyo. Read more here: msd.gl/4fvfUNR

MSD (@msdinvents) 's Twitter Profile Photo

Today, we announced the acquisition of a novel investigational bispecific antibody from Curon Biopharma. Learn how this further expands and diversifies our growing pipeline, with potential applications in B-cell malignancies and autoimmune diseases: msd.gl/4dj9EY0

Today, we announced the acquisition of a novel investigational bispecific antibody from Curon Biopharma. Learn how this further expands and diversifies our growing pipeline, with potential applications in B-cell malignancies and autoimmune diseases: msd.gl/4dj9EY0
MSD (@msdinvents) 's Twitter Profile Photo

Today, we announced the completion of our acquisition of a novel investigational bispecific antibody from Curon Biopharmaceutical offering applications in B-cell malignancies and autoimmune diseases and further broadening our pipeline. Read more: msd.gl/4epGBCK

MSD (@msdinvents) 's Twitter Profile Photo

Today, we shared positive results from our late-stage clinical program in respiratory syncytial virus (#RSV) disease. Learn more here: msd.gl/48grqJF

MSD (@msdinvents) 's Twitter Profile Photo

Today, we announced an agreement to acquire Modifi Bio and the company’s preclinical compounds designed to exploit DNA repair defects in difficult to treat forms of #cancer.

Today, we announced an agreement to acquire 
Modifi Bio and the company’s preclinical compounds designed to exploit DNA repair defects in difficult to treat forms of #cancer.
MSD (@msdinvents) 's Twitter Profile Photo

Today we announced an exclusive global license to develop, manufacture and commercialize a novel investigational bispecific antibody from LaNova Medicines Ltd. Learn more: msd.gl/40KiGtC

Today we announced an exclusive global license to develop, manufacture and commercialize a novel investigational bispecific antibody from LaNova Medicines Ltd. Learn more: msd.gl/40KiGtC
MSD (@msdinvents) 's Twitter Profile Photo

Today we announced an exclusive global license to develop, manufacture and commercialize an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma. Learn more: msd.gl/4gG12Ma

Today we announced an exclusive global license to develop, manufacture and commercialize an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma. Learn more: msd.gl/4gG12Ma
MSD (@msdinvents) 's Twitter Profile Photo

Our Q4 and full-year 2024 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/40JwsuT

Our Q4 and full-year 2024 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/40JwsuT
MSD (@msdinvents) 's Twitter Profile Photo

Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Learn more: msd.gl/4c1Fh8I

Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Learn more: msd.gl/4c1Fh8I